Avecho Biotechnology Limited - Asset Resilience Ratio
Avecho Biotechnology Limited (OEZ) has an Asset Resilience Ratio of 1.18% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OEZ current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2018)
This chart shows how Avecho Biotechnology Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Avecho Biotechnology Limited.
Liquid Assets Composition Over Time
This chart breaks down Avecho Biotechnology Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read OEZ total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €56.73K | 1.18% |
| Total Liquid Assets | €56.73K | 1.18% |
Asset Resilience Insights
- Limited Liquidity: Avecho Biotechnology Limited maintains only 1.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avecho Biotechnology Limited Industry Peers by Asset Resilience Ratio
Compare Avecho Biotechnology Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Avecho Biotechnology Limited (2017–2018)
The table below shows the annual Asset Resilience Ratio data for Avecho Biotechnology Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 1.18% | €56.73K ≈ $66.32K |
€4.80 Million ≈ $5.61 Million |
-4.34pp |
| 2017-12-31 | 5.52% | €454.73K ≈ $531.62K |
€8.24 Million ≈ $9.63 Million |
-- |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more